CURA enters September with an unusual combination: a stock that has gained 10% over the past month, short sellers quietly exiting, and a 90th-percentile earnings estimate momentum reading — yet its closest peers are mostly heading the other way this week.
The clearest setup in the lending market is one of indifference rather than aggression. Short interest has drifted lower all month, declining around 6% from July-end levels to roughly 0.22% of the free float — a figure so low it barely registers as a bearish thesis. More telling is the borrow availability picture: with availability running at 1,322%, there are approximately thirteen shares available to lend for every one currently borrowed. That is deep in loose territory, well above even the 52-week minimum of 496%, confirming that no meaningful short-side demand has emerged to challenge the recent rally. Cost to borrow has also been falling — from a peak above 4.4% in early August to 2.19% today — a further sign the borrow market is relaxing, not tightening, as the price rises.
The Street angle is more complicated. Analyst data is absent from this snapshot, so the narrative here belongs to the factor scores instead. The standout is the 90-day EPS momentum rank — a 99th-percentile reading, meaning estimate revisions have been running higher more consistently than almost every other name in the universe. That is a meaningful signal. Yet it sits alongside an EPS surprise rank in the 8th percentile, meaning that when results actually land, they tend to disappoint relative to what was pencilled in. The EV/EBITDA multiple has compressed from above 11.7x thirty days ago to 11.0x now, a modest valuation improvement against the backdrop of a rising share price — implying EBITDA estimates have moved up faster than the stock. The PE ratio is deeply negative, reflecting ongoing losses at the operating level, and the price-to-book at 4.7x looks full for a cannabis multi-state operator still working toward consistent profitability.
The ownership picture carries one notable thread. The Chief Legal Officer, Peter Clateman, has been selling shares on a near-fortnightly cadence since at least July 1 — six transactions totalling roughly 53,000 shares spread across four separate dates, with the most recent on August 26. Each sale is small in absolute dollar terms (the largest batch around $94,000), and the regularity suggests a pre-arranged plan rather than a discretionary exit. It is worth noting separately that Boris Jordan, among the largest named holders in the data, reduced his disclosed position by 878,333 shares as of mid-July — a more substantial move. Against this, AdvisorShares remains the dominant institutional force with nearly 4.7% of shares, and BlackRock added modestly in July.
Peer performance creates a mild headwind for the narrative. On the day, most cannabis comparables pulled back: WEED dropped over 2%, GTII fell 2.5%, and VRNO was off around 2.4%. Only TRLV moved in the same direction as CURA, gaining 2%. Over the week, WEED has shed more than 8% — a notable contrast to CURA's flat-to-positive hold. That relative resilience is real, but it cuts both ways: if the sector catches a broader bid, CURA has less room to outperform on the recovery; if the sector sells off further, CURA's cushion looks thin given it has already moved 10% in a month.
The next scheduled earnings date is November 6. Between now and then, the tension worth watching is whether the 99th-percentile estimate momentum translates into an actual beat — or whether the historically low EPS surprise rank reasserts itself and the compression in the multiple reverses.
See the live data behind this article on ORTEX.
Open CURA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
